Budget 2022: PHARMAC boost leaves patients cold: 'it won't be enough'

19 May 2022 - PHARMAC has had its biggest ever funding boost, but some New Zealanders fear it still won’t ...

Read more →

Medicines Australia puts spotlight on reform priority for the next Government

20 May 2022 - Medicines Australia has set the scene for major health reform by the next Government by alerting ...

Read more →

Plea to make new depression 'spray' affordable

19 May 2022 - Mental health experts say a nasal spray to help relieve depression should be subsidised to make ...

Read more →

Major parties committed to major medicines policy reform and reviews – whoever wins on Saturday

19 May 2022 - Medicines Australia has been assured in official communications from the respective Campaign Headquarters that both the ...

Read more →

BMS’ Sprycel reimbursement criteria to be broadened for paediatric Philadelphia chromosome positive ALL

19 May 2022 - The state health insurance review agency said it would broaden the reimbursement criteria for Sprycel (dasatinib), ...

Read more →

Budget 2022: critically ill patients 'bitterly disappointed' by PHARMAC funding

19 May 2022 - Critically ill patients say they're "bitterly disappointed" by today's PHARMAC Budget announcement and were left looking ...

Read more →

G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit

19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...

Read more →

SIGA receives approval from the FDA for intravenous formulation of Tpoxx (tecovirimat)

19 May 2022 - FDA approval provides an important option for those unable to take oral formulation of Tpoxx. ...

Read more →

EMA accepts filing of marketing authorisation application for Valneva’s inactivated COVID-19 vaccine candidate

19 May 2022 -  2022 – Valneva today confirmed that the EMA has accepted the filing of a marketing authorisation ...

Read more →

Multiple funding proposals being considered by PHARMAC

19 May 2022 - PHARMAC has issued three consultations today on proposals to fund medicines for conditions including cancer, multiple sclerosis, ...

Read more →

COVID-19 vaccine weekly safety report (19 May 2022)

19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...

Read more →

Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread

17 May 2022 - A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the ...

Read more →

PHARMAC will use biggest budget increase ever to fund more medicines for more New Zealanders

19 May 2022 - PHARMAC welcomes the $191 million increase to its pharmaceutical budget over the next two years.  ...

Read more →

CMS unveils more user friendly Medicare website

18 May 2022 - New Medicare.gov will incorporate public feedback and make it easier to compare, choose, and understand Medicare ...

Read more →

Alnylam announces Health Canada authorisation of Oxlumo (lumasiran), the first and only treatment for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients

18 May 2022 - Authorization based on two pivotal Phase 3 trials, ILLUMINATE-A and ILLUMINATE-B; showing significant reduction in urinary ...

Read more →